ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 7ÔÂ15ÈÕ£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬ËÕÖÝ¿µÄþ½ÜÈðÉ걨µÄ1ÀàÐÂÒ©KN069×¢ÉäÒº»ñÅúÁÙ´²£¬£¬£¬ÊÊÓÃÓÚ·ÊÅÖ»¼Õß»ò°éÓÐÖÁÉÙÒ»Öֺϲ¢Ö¢£¨Èç¸ßѪÌÇ¡¢¸ßѪѹ¡¢ÑªÖ¬Òì³£¡¢Ö¬·¾¸Î¡¢ÛÕ±ÕÐÔ˯ÃߺôÎüÔÝÍ£×ÛºÏÕ÷£©µÄ³¬ÖØ»¼ÕßµÄÌåÖØ¹ÜÀí¡£¡£¡£¡£
2. 7ÔÂ16ÈÕ£¬£¬£¬ÔªôàÉúÎTenacia Biotechnology£©Ðû²¼ÆäÒý½ø×ÔMarinus¹«Ë¾µÄµÄ¼ÓÄÇË÷Áú¿Ú·þ»ìÐü¼Á£¨ÉÌÆ·Ãû£ºÔóÔª°²£©ÒÑÔÚÖйú»ñÅúÉÏÊУ¬£¬£¬ÓÃÓÚÖÎÁÆ2Ëê¼°ÒÔÉÏϸ°ûÖÜÆÚÂѰ×ÒÀÀµÐÔ¼¤Ã¸5£¨CDKL5£©È±·¦Ö¢»¼Õßñ²ðﱬ·¢¡£¡£¡£¡£ÕâÊÇÒ»¿î°ÐÏòGABAAÊÜÌåµÄÑôÐԱ𹹵÷Àí¼Á¡£¡£¡£¡£
3. 7ÔÂ16ÈÕ£¬£¬£¬ÔÙ¶¦Ò½Ò©ºÍargenx¹«Ë¾Ðû²¼°¬¼ÓĪµÂ¦Á×¢ÉäÒº£¨Æ¤ÏÂ×¢É䣩µÄÐÂÒ©ÉÏÊÐÉêÇëÒÑ»ñNMPAÅú×¼£¬£¬£¬ÓëͨÀýÖÎÁÆÒ©ÎïÁªºÏ£¬£¬£¬ÓÃÓÚÖÎÁÆÒÒõ£µ¨¼îÊÜÌ壨AChR£©¿¹ÌåÑôÐԵijÉÈËÈ«ÉíÐÍÖØÖ¢¼¡ÎÞÁ¦£¨gMG£©»¼Õß¡£¡£¡£¡£
4. 7ÔÂ16ÈÕ£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬ÏÈÉùÒ©ÒµÁªºÏÉ걨µÄÑÎËá´ïÀûÀ×ÉúƬÐÂÒ©ÉÏÊÐÉêÇëÒÑ»ñµÃÊÜÀí¡£¡£¡£¡£Æ¾Ö¤ÏÈÉùÒ©Òµ¹ûÈ»×ÊÁÏ£¬£¬£¬ÕâÊÇÆäÓëÈðÊ¿Idorsia¹«Ë¾ÏàÖú¿ª·¢µÄ¿¹Ê§ÃßÒ©£¬£¬£¬ÎªÒ»¿î˫ʳÓûËØÊÜÌåÞ׿¹¼Á¡£¡£¡£¡£
1. 7ÔÂ16ÈÕ£¬£¬£¬ÎÀ²Ä¹ÙÍøÐû²¼ÐÂÎÅ£¬£¬£¬¹«Ë¾Óë×ôÌÙÖÆÒ©¸æ¿¢ÔÊÐíÐÒ飬£¬£¬ÊÚÓè×ôÌÙÖÆÒ©ÔÚÑÇÖ޺ʹóÑóÖÞµØÇø¿ª·¢ºÍÉÌÒµ»¯¿¹Õæ¾ú¼Á Fosravuconazole µÄ¶À¼ÒȨÁ¦¡£¡£¡£¡£Æ¾Ö¤ÐÒéÌõ¿î£¬£¬£¬ÎÀ²Ä½« Fosravuconazole ÔÚÖ¸¶¨¹ú¼ÒºÍµØÇøµÄ֪ʶ²úȨ¶À¼ÒÔÊÐí¸ø×ôÌÙÖÆÒ©¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬±±¾©ÐºÍҽѧԺºÕ½ÝԺʿÍŶÓÔÚ Cancer Cell ½ÒÏþÑо¿Ð§¹û Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators£¬£¬£¬Ê¹Óà ATAC-seq ¼¼Êõ¡¢¶àÖØÃâÒß×黯£¨mIHC£©ºÍ¿Õ¼äת¼×é¼¼Êõ£¬£¬£¬ÏµÍ³ÆÊÎöÁË¿ç×éÖ¯Éñ¾ÄÚÉøÍ¸°©£¨NEC£©ÒìÖÊÐÔ£¬£¬£¬Ê×´ÎÀֳɽ¨Éè 5 Ö¸±ê·º°©»¼Õß·Ö²ãϵͳ¡£¡£¡£¡£ÎªÃ÷È·Ö×ÁöÒìÖÊÐÔ£¬£¬£¬ÒÔ¼°ÁÙ´²Éϰ©Ö¢»¼ÕߵķֲãÕïÁƺÍÔ¤ºóÌṩÁËÖ÷ÒªÒÀ¾Ý¡£¡£¡£¡£
[1]Wang Z, Liu C, Zheng S, et al. Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators. Cancer Cell. 2024 Jun 10;42(6):1106-1125.e8. doi: 10.1016/j.ccell.2024.05.002.
Ïà¹ØÐÂÎÅ